(LCI) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 21, 2013
(Stock Blog Hub,
3/5/13)
UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies.
The Candidate
Tozadenant is an...(read more)
(Stock Blog Hub,
10/9/12)
Lannett Company, Inc. (LCI) recently announced that the US Food and Drug Administration (FDA) granted approval to the company’s abbreviated new drug application (ANDA) for its generic...(read more)
(Benzinga,
9/13/10)
Lannett Co. Inc. (NYSE: LCI) reports Q4 EPS of $0.11, versus the consensus of $0.08. Lannett Co. Inc. reports revenues of $33.8 million, versus the consensus of $32.03 million.
"Strong sales of our pain management drugs in the...(read more)
Lannett Co (LCI) Company Overview
There is no analysis for LCI yet. But you can go to Wikinvest to help create one!
What's in this LCI analysis on Wikinvest...
